Trial Profile
An Open Study of Atomoxetine (LY139603) in Adult Subjects With Attention-Deficit/Hyperactivity Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 25 Dec 2009 Actual patient number (45) added as reported by ClinicalTrials.gov.
- 30 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Sep 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.